Literature DB >> 22103444

Suppression of EGFR autophosphorylation by FKBP12.

Sebastian Mathea1, Sen Li, Angelika Schierhorn, Günther Jahreis, Cordelia Schiene-Fischer.   

Abstract

FK506 binding proteins (FKBPs) represent a subfamily of peptidyl prolyl cis/trans isomerases that can control receptor-mediated intracellular signaling. The prototypic PPIase FKBP12 functionally interacts with EGFR. FKBP12 was shown to inhibit EGF-induced EGFR autophosphorylation with all internal phosphorylation sites equally affected. The inhibition of EGFR catalytic activity is conducted by targeting the EGFR kinase domain. The change of intracellular FKBP12 levels resulted in a change of EGFR autophosphorylation level. Collectively, our results demonstrate that FKBP12 forms an endogenous inhibitor of EGFR phosphorylation directly involved in the control of cellular EGFR activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22103444     DOI: 10.1021/bi2013855

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  FKBPs and the Akt/mTOR pathway.

Authors:  Felix Hausch; Christian Kozany; Marily Theodoropoulou; Anne-Katrin Fabian
Journal:  Cell Cycle       Date:  2013-07-01       Impact factor: 4.534

2.  The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes.

Authors:  Silvia Colucci; Alessia Pagani; Mariateresa Pettinato; Irene Artuso; Antonella Nai; Clara Camaschella; Laura Silvestri
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

3.  FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.

Authors:  Edda Spiekerkoetter; Xuefei Tian; Jie Cai; Rachel K Hopper; Deepti Sudheendra; Caiyun G Li; Nesrine El-Bizri; Hirofumi Sawada; Roxanna Haghighat; Roshelle Chan; Leila Haghighat; Vinicio de Jesus Perez; Lingli Wang; Sushma Reddy; Mingming Zhao; Daniel Bernstein; David E Solow-Cordero; Philip A Beachy; Thomas J Wandless; Peter Ten Dijke; Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2013-07-15       Impact factor: 14.808

4.  FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.

Authors:  Mingyou Xing; Jun Wang; Qin Yang; Yu Wang; Jiansha Li; Jing Xiong; Sheng Zhou
Journal:  Cancer Chemother Pharmacol       Date:  2019-08-19       Impact factor: 3.333

5.  Kallikrein-related peptidase 8 is expressed in myocardium and induces cardiac hypertrophy.

Authors:  Buqing Cao; Qing Yu; Wei Zhao; Zhiping Tang; Binhai Cong; Jiankui Du; Jianqiang Lu; Xiaoyan Zhu; Xin Ni
Journal:  Sci Rep       Date:  2016-01-29       Impact factor: 4.379

6.  Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.

Authors:  Lucia Raimondo; Valentina D'Amato; Alberto Servetto; Roberta Rosa; Roberta Marciano; Luigi Formisano; Concetta Di Mauro; Roberta Clara Orsini; Priscilla Cascetta; Paola Ciciola; Ana Paula De Maio; Maria Flavia Di Renzo; Sandro Cosconati; Agostino Bruno; Antonio Randazzo; Filomena Napolitano; Nunzia Montuori; Bianca Maria Veneziani; Sabino De Placido; Roberto Bianco
Journal:  Oncotarget       Date:  2016-06-28

7.  FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2.

Authors:  T Liu; J Xiong; S Yi; H Zhang; S Zhou; L Gu; M Zhou
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.